March 15 (Reuters) - ** Shares of cell-based medical
device company Thermogenesis Holding THMO.O nearly double to
$4.16
** THMO says it will roll out a facility in Sacramento
comprising 12 class-7 ReadyStart cGMP Suites available for lease
later this year by early-stage life science and cell gene
therapy cos
** If fully occupied, facility is anticipated to generate an
estimated $10-16 mln in annual revenue
** The roll-out is part of co's previously announced plan to
transform to a contract development and manufacturing
organization in cell-gene therapy field
** Facility is expected to be available for customers in
second or third quarter of this year
** YTD THMO was up 27.5%
(Reporting by Vaibhav Sadhamta in Bengaluru)
((Vaibhav.Sadhamta@thomsonreuters.com;))